Is GSK’s share price a brilliant bargain after this new vaccines deal?

The GSK share price continues to weaken despite a major vaccines deal with German company CureVac. Is now the time to pile in?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s been a tough few weeks for the GSK (LSE:GSK) share price. Even news of a major vaccines agreement on Wednesday (3 July) hasn’t helped it to recover ground.

At £15.03 per share, the FTSE 100 firm was last trading marginally lower in mid-week trading. It has now lost all the gains it had earlier enjoyed in 2024.

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

I think GSK shares might now be a brilliant dip buy. Here’s why I think value investors should give it serious consideration right now.

Should you invest £1,000 in Scottish Mortgage right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Scottish Mortgage made the list?

See the 6 stocks

Big news

To build its position in the lucrative vaccines market, GSK has announced a deal with German company, CureVac. It plans to pay up to €1.4bn to the cash-strapped company to take development control for certain vaccines.

GSK said it will acquire “full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and COVID-19, including combinations”.

It will pay €400m up front, and up to another €1.05bn as certain development, regulatory, and sales milestones are met. The two companies have been working closely together since 2020 to develop mRNA vaccines for infectious diseases.

Huge opportunity

The agreement could significantly boost the profits GSK makes in a fast-growing marketplace.

Analysts at Statista, for instance, think total revenues from vaccine products will soar 28% between 2025 and 2028, to $88.6bn. Demand will driven by increased government promotion of vaccination programs and heightened consumer awareness of their life-saving benefits following the Covid-19 crisis.

Encouragingly, GSK is already establishing itself as a star player here. Sales of its vaccines like the blockbuster Shingrix treatment soared 16% in the first quarter of 2024 (at constant currencies), to £2.3bn.

Turnover was also helped by new product rollouts in the quarter. While getting product from lab bench to market can be a bumpy ride, a strong product pipeline suggests GSK is in good shape to keep this momentum going.

Risks

Investing in GSK doesn’t come without peril, however. The pharma sector is strictly governed, and an adverse decision from regulators can cost a fortune in lost revenues and extra R&D costs.

Last month, for instance, the US Centers for Disease Control and Prevention (CDC) pledged to restrict rollout of the respiratory syncytial virus (RSV) vaccine across older age groups. Jefferies analysts have said the decision could reduce the addressable market to 55m doses from a prior projection of 93m.

Another worry for GSK is the possibility of huge penalties related to Zantac. A judge in Delaware ruled last month that expert witnesses could be permitted in jury trials in cases claiming the heartburn drug causes cancer.

A top value stock

But all things considered, I still think the drugs giant has significant investment appeal. And particularly at current rock-bottom prices.

Its recent slump leaves GSK’s share price trading on a forward price-to-earnings (P/E) ratio of just 9.4 times. This makes it one of the cheapest companies in the pharma sector (AstraZeneca, for example, trades on a multiple of 18.8 times).

Investors can now also grab a 4% dividend yield from the drugs giant. As a whole, I think it’s an excellent value share for investors to consider this July, with Wednesday’s update providing even more reason to be optimistic.

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Market Movers

The flag of the United States of America flying in front of the Capitol building
Investing Articles

10 FTSE shares falling today after President Trump’s tariffs bombshell!

Our writer explains why JD Sports Fashion from the FTSE 100 and a diverse bunch of other UK stocks are…

Read more »

Investing Articles

Down 11% today, is this FTSE 250 share NOW a top dip buy?

This FTSE 250 share has lost around a fifth of its value during the last 12 months. Is it now…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

What’s happening to the Lloyds share price?

The Lloyds Bank share price has gained 31% in the past 12 months, but it could be facing its sternest…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

Down 13% in the FTSE 250! Why did Pets at Home stock sell off today?

Our writer looks at the worst-performing stock in the FTSE 250 today to see what has gone wrong and whether…

Read more »

Investing Articles

Up 46% in a fortnight! Is this soaring ex-penny stock still a FTSE gem at 59p?

SRT Marine Systems (LON:SRT) has been one of the very best FTSE small-cap stocks to own after surging 132% in…

Read more »

Investing Articles

This FTSE 100 fashion icon just broke the £1bn profit ceiling! What’s next?

FTSE 100 fashion retailer Next posted £1bn annual profit in this morning's results. In light of recent trade tariffs, is…

Read more »

Investing Articles

Record £1bn profit gives the Next share price a boost. Is it still cheap?

The Next share price has been soaring ahead of sector rivals, and the latest full-year results might just give us…

Read more »

Investing Articles

An activist thinks the Smiths Group share price is too low. These first-half results might show why

The Smiths Group share price has had a solid five years, and City analysts are predicting yet more years of…

Read more »